Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Nov
27
Today In Oncology
FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma
AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible
External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer
No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer
ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo